“Regenerative” has become one of the most commercially overloaded words in aesthetic medicine. Every modality from PRP to exosomes to NAD+ gets the label, but the evidence behind them spans multiple orders of magnitude — from multiple randomized controlled trials to early preclinical data to promising-but-regulatory-uncertain territory.
Providers who can give patients an accurate, calibrated picture of each treatment will earn the kind of trust no marketing claim can buy. Those who overpromise are one adverse event or one well-researched patient away from a credibility problem.
What you will learn in this article:
PRP has the deepest evidence base of any regenerative modality in aesthetic medicine — multiple randomized controlled trials for both skin rejuvenation and hair restoration, clear regulatory standing, and years of real-world clinical data behind it.
A histologic study by Abuaf et al. found an 89.05% improvement in dermal collagen optical density in PRP-treated areas, a striking finding from a small, non-randomized study of 20 patients, worth citing with that context in place.
A 2024 systematic review confirms the body of RCT-level evidence supporting PRP across skin rejuvenation and androgenetic alopecia applications. Not all PRP protocols are equivalent; technique and concentration matter, but the modality itself sits on solid ground. It’s the benchmark against which other regenerative treatments should be evaluated.
Polynucleotides and PDRN (the treatment behind the viral “salmon facial” trend) have been mainstream in European and Asian aesthetic medicine for years. The U.S. market is catching up fast.
The mechanism is well-characterized: salmon-derived DNA fragments stimulate tissue repair via PDRN receptors and drive collagen synthesis, producing measurable improvements in skin hydration, texture, and elasticity. The safety profile is well-established across a large international evidence base.
For providers building a regenerative menu on defensible ground, polynucleotides are the strongest addition after PRP — and for practices targeting the skin quality concerns that GLP-1 and aging patients both present with, they’re particularly well-suited.
Two systematic reviews published in early 2026 — Alzahrani et al. in Dermatology Practical & Conceptual and Flores Rodríguez et al. in Cureus — both found positive associations for skin elasticity, hydration, and wrinkle depth. Both also concluded that larger, standardized trials are still needed.
The science is genuinely interesting. The regulatory situation is not: no exosome product has FDA approval for aesthetic use, and the FDA’s position applies regardless of delivery method once any structure-or-function claim is made. Consult legal counsel before adding any exosome product to your treatment menu.
For a full breakdown of the regulatory landscape and enforcement actions to date, see IAPAM’s April 2026 Aesthetic Medicine Update.
Cell-assisted lipotransfer (fat grafting enriched with stromal vascular fraction containing stem cells) has a published evidence base, but the results are mixed. Some studies report improved graft retention compared to conventional fat grafting; others have found no statistically significant difference.
The technique is real and the interest is legitimate. What it requires is equally real: advanced surgical skill, proper credentialing, and a clear understanding that these are investigational techniques in a regulatory environment that demands caution. SVF and stem cell therapies are worth tracking as the evidence base develops. For most aesthetic practices, they’re not menu items right now.
The science behind NAD+ is compelling. It governs cellular senescence and DNA repair, and IV delivery bypasses the first-pass metabolism limitations of oral precursors. Early-phase human trials are underway across longevity and metabolic applications. Skin-specific clinical efficacy data is still preliminary.
For aesthetic providers, NAD+ is worth understanding as part of the broader longevity medicine conversation — particularly for practices serving weight management patients with metabolic and cellular aging concerns. The full clinical and business case for adding IV NAD+ to a practice is covered in NAD+ Therapy in 2026: What Aesthetic and Weight Management Providers Need to Know.
Patients are researching these treatments before they arrive. They’ve seen exosome ads, read about stem cells, and heard about NAD+ from longevity influencers. The providers who handle these conversations well lead with what’s proven, are honest about what’s emerging, and don’t make promises the evidence doesn’t support. A working framework:
Patients who get that kind of calibrated honesty become long-term patients. Those who get overpromised become one-visit patients who leave reviews.
For a broader look at where aesthetic medicine is heading across all modalities, the 2026 Aesthetic Medicine Trends resource and the IAPAM Skincare Library are regularly updated references.
Providers who want to build a regenerative aesthetic practice with the clinical depth to evaluate each modality on its merits — and adapt as the evidence and regulatory landscape evolve — need training that covers the full picture.
The Certified Aesthetic Provider Program covers PRP, stem cells, longevity medicine, and emerging regenerative therapies with the clinical grounding to make sound decisions about what to offer and when.
For providers ready to add PRP within a broader facial rejuvenation framework, the Facial Rejuvenation Certification is the focused path. A dedicated Hair Restoration course covering PRP for androgenetic alopecia is coming soon — watch for that addition to IAPAM’s training catalog.
What is the difference between PRP and exosomes for aesthetic use?
PRP uses the patient’s own platelets to deliver growth factors that stimulate collagen production and tissue repair — a well-established mechanism with multiple RCTs behind it and clear regulatory standing. Exosomes are extracellular vesicles that carry signaling molecules between cells, with promising early human data from two 2026 systematic reviews. The key distinction in 2026 is regulatory: PRP has a clear path to clinical use; exosomes do not yet have FDA approval for aesthetic applications, and the FDA’s enforcement position is active. PRP is the appropriate choice for providers building a regenerative menu now.
Is PDRN available in the United States?
PDRN and polynucleotide products are entering the U.S. market, though availability varies by supplier and product formulation. They have been mainstream in European and Asian aesthetic medicine for years with an established safety and efficacy record. Providers interested in adding PDRN should verify the specific product’s regulatory status and supplier credibility before purchasing. IAPAM’s dedicated PDRN article covers the current landscape in detail.
What regenerative aesthetic treatments are FDA approved?
PRP operates within a clear regulatory framework and is widely used in aesthetic medicine. Polynucleotides and PDRN are regulated as cosmetic or drug products depending on the specific claims made — providers should verify the product they’re using. Exosomes have no FDA approval for aesthetic use as of 2026. SVF and stem cell therapies are investigational. NAD+ for IV use is administered under provider discretion as part of wellness protocols but lacks specific FDA approval for aesthetic indications.
How do I talk to patients who come in asking about exosome therapy?
Be direct and factual. No exosome product is currently FDA-approved for aesthetic use, and the FDA has issued warning letters to clinics offering unapproved products. The science is genuinely interesting and the regulatory landscape may evolve — you’re watching it closely. In the meantime, PRP and polynucleotides offer regenerative results on solid clinical and regulatory ground. Most patients who came in asking about exosomes because they saw an ad respond well to a provider who explains the situation clearly rather than dismissing their question.
Are stem cell treatments safe for aesthetic use?
Cell-assisted lipotransfer using stromal vascular fraction has published evidence for improved graft retention compared to conventional fat grafting. The safety profile of the procedure depends heavily on technique, training, and the clinical setting. These are not off-the-shelf treatments — they require advanced surgical skill and a clear understanding of their investigational status. For most aesthetic practices, the more relevant question is whether the provider has the training, credentialing, and clinical infrastructure to offer them responsibly. Many don’t, and that’s not a failure — it’s accurate self-assessment.
What role does NAD+ play in aesthetic medicine?
NAD+ governs cellular senescence and DNA repair, and IV delivery bypasses the absorption limitations of oral precursors — making it meaningfully different from supplement-grade alternatives. Early-phase human trials are underway across longevity and metabolic applications. Aesthetic-specific clinical data is still early. For practices serving patients with both weight management and aesthetic goals — particularly those interested in the longevity medicine conversation — NAD+ IV therapy fits naturally into a broader wellness offering. It’s not a standalone aesthetic treatment yet; it’s a high-value addition to a practice already oriented around the whole patient.
Get Your Free GLP-1 Quick Start Action Plan
References:
1. Abuaf et al. — Histologic Evidence of New Collagen Formation Using Platelet Rich Plasma in Skin Rejuvenation — Annals of Dermatology — 2016
2. PMC — Platelet-Rich Plasma in Dermatology: New Insights on the Horizon — 2024
3. Alzahrani et al. — Exosome-Based Therapies in Dermatology: A Systematic Review — Dermatology Practical & Conceptual — January 2026
4. Flores Rodríguez et al. — Exosomes in Aesthetic Medicine: A Systematic Review — Cureus — February 2026
5. U.S. Food & Drug Administration — Public Safety Notification: Exosome Products
6. MDPI Cosmetics — Stromal Vascular Fraction and Cell-Assisted Lipotransfer in Aesthetic Medicine — 2024
7. PMC — NAD+ in Cellular Senescence and Aging: Current Evidence and Clinical Implications — 2026
